16.03.2015 • NewsBayerCABB GroupCEO

CABB names new CEO: Peter Vanacker to succeed Martin Wienkenhöver

Effective April 1, 2015, Peter Vanacker will succeed Dr. Martin Wienkenhöver as CEO of CABB, a leading global fine chemicals manufacturer.

Peter Vanacker to succeed Dr. Martin Wienkenhoever
Peter Vanacker to succeed Dr. Martin Wienkenhoever

Wienkenhöver will retire later this year after a transition period, in which he will support the new CEO in taking over all responsibilities. His experience will not be lost for CABB, since he has agreed to serve on the company's advisory board, starting later this year.

Peter Vanacker (49) has served for about 10 years as member of the executive committee of Bayer MaterialScience and ran its global polyurethanes business from 2004 to 2011. He was also Chief Marketing and Innovation Officer of Bayer MaterialScience. Most recently he has been CEO of Treofan Group, a private equity owned global technology leader in bi-axially oriented polypropylene films (BOPP).

"We are really enthused that we have won Peter Vanacker as CEO of CABB Group", said Torsten Vogt, Partner and Co-Head of the Industrials team at private equity firm Permira. "With his deep understanding of the chemical industry and his broad experience in senior positions at international companies, Peter is optimally equipped to lead CABB into the next phase of sustainable growth. He has the skills to consolidate CABB's position as a valued partner for the global life science majors and many important customers in the chemicals industry."

"My focus will be on further profitable growth in close partnership with our valued customers", said Peter Vanacker.

Company

CABB Group GmbH

Otto-Volger-Straße 3c
65843 Sulzbach am Taunus

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.